Merck serves up the right medicine
Germany’s Merck KGaA’s Eu3.2bn bond came under fire last week for what some described as overly generous pricing. But this wasn’t an exercise in setting price benchmarks. Surety of funds has to be the main concern in any acquisition-related funding, and in that respect, Merck’s strategy was spot on.
Unlock this article.
The content you are trying to view is exclusive to our subscribers.
To unlock this article:
- ✔ 4,000 annual insights
- ✔ 700+ notes and long-form analyses
- ✔ 4 capital markets databases
- ✔ Daily newsletters across markets and asset classes
- ✔ 2 weekly podcasts